Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.
Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, CT, USA.
Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(11):763-777. doi: 10.1080/14779072.2023.2286011. Epub 2023 Dec 10.
The prevalence of carotid artery stenosis in the general population is approximately 3%, but approximately 20% among people with acute ischemic stroke. Statins are recommended by multiple international guidelines as the drug of choice for lipid control in people with asymptomatic or symptomatic carotid artery stenosis due to their lipid-lowering and other pleiotropic effects.
This review discusses the guidelines for statin usage as a cornerstone in the prevention and management of atherosclerotic carotid artery disease and the impact of statins on stroke incidence and mortality. Statin side effects, alternative therapy, and genetic polymorphisms are reviewed.
Statin therapy is associated with a decreased incidence of stroke and mortality as well as improved outcomes for patients treated with carotid revascularization. Statins are a safe and effective class of medications, but the initiation of therapy warrants close monitoring to avoid rare and potentially serious side effects. Lack of clinical efficacy or the presence of side effects suggests a need for treatment with an alternative therapy such as PCSK9 inhibitors. Understanding the interplay between the mechanisms of statins and PCSK9 inhibition therapies will allow optimal benefits while minimizing risks. Future research into genetic polymorphisms may improve patient selection for personalized therapy.
在普通人群中,颈动脉狭窄的患病率约为 3%,但在急性缺血性脑卒中患者中约为 20%。由于他汀类药物具有降脂作用和其他多效性作用,因此多项国际指南均推荐将其作为无症状或有症状颈动脉狭窄患者血脂控制的首选药物。
本文讨论了将他汀类药物作为预防和治疗动脉粥样硬化性颈动脉疾病的基石的指南,以及他汀类药物对卒中发生率和死亡率的影响。还讨论了他汀类药物的副作用、替代疗法和基因多态性。
他汀类药物治疗可降低卒中发生率和死亡率,并改善颈动脉血运重建治疗患者的预后。他汀类药物是一类安全有效的药物,但在开始治疗时需要密切监测,以避免罕见且潜在严重的副作用。如果缺乏临床疗效或出现副作用,则需要使用替代疗法,如 PCSK9 抑制剂。了解他汀类药物和 PCSK9 抑制疗法之间的相互作用机制,将有助于在最大限度降低风险的同时获得最佳疗效。未来对基因多态性的研究可能会改善个性化治疗的患者选择。